NH SPAC 2
Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testi… Read more
NH SPAC 2 (206640) - Total Assets
Latest total assets as of September 2025: ₩274.58 Billion KRW
Based on the latest financial reports, NH SPAC 2 (206640) holds total assets worth ₩274.58 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NH SPAC 2 - Total Assets Trend (2015–2024)
This chart illustrates how NH SPAC 2’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
NH SPAC 2 - Asset Composition Analysis
Current Asset Composition (December 2024)
NH SPAC 2's total assets of ₩274.58 Billion consist of 53.3% current assets and 46.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩47.94 Billion | 18.8% |
| Accounts Receivable | ₩29.27 Billion | 11.5% |
| Inventory | ₩38.75 Billion | 15.2% |
| Property, Plant & Equipment | ₩61.87 Billion | 24.3% |
| Intangible Assets | ₩5.81 Billion | 2.3% |
| Goodwill | ₩316.30 Million | 0.1% |
Asset Composition Trend (2015–2024)
This chart illustrates how NH SPAC 2's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NH SPAC 2's current assets represent 53.3% of total assets in 2024, a decrease from 62.3% in 2015.
- Cash Position: Cash and equivalents constituted 18.8% of total assets in 2024, down from 22.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 24.3% of total assets.
NH SPAC 2 Competitors by Total Assets
Key competitors of NH SPAC 2 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
NH SPAC 2 - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - NH SPAC 2 generates 0.54x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, NH SPAC 2 generates $ 10.70 in net profit.
NH SPAC 2 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.05 | 7.12 | 3.65 |
| Quick Ratio | 3.36 | 5.33 | 2.92 |
| Cash Ratio | 0.00 | 1.82 | 0.00 |
| Working Capital | ₩97.25 Billion | ₩ 119.75 Billion | ₩ 88.14 Billion |
NH SPAC 2 - Advanced Valuation Insights
This section examines the relationship between NH SPAC 2's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.26 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 11.7% |
| Total Assets | ₩254.67 Billion |
| Market Capitalization | $110.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values NH SPAC 2's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: NH SPAC 2's assets grew by 11.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NH SPAC 2 (2015–2024)
The table below shows the annual total assets of NH SPAC 2 from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩254.67 Billion | +11.75% |
| 2023-12-31 | ₩227.90 Billion | +16.48% |
| 2022-12-31 | ₩195.66 Billion | +1.78% |
| 2021-12-31 | ₩192.24 Billion | +17.60% |
| 2020-12-31 | ₩163.47 Billion | +61.44% |
| 2019-12-31 | ₩101.26 Billion | -2.11% |
| 2018-12-31 | ₩103.44 Billion | -4.37% |
| 2017-12-31 | ₩108.17 Billion | +19.14% |
| 2016-12-31 | ₩90.79 Billion | +26.62% |
| 2015-12-31 | ₩71.71 Billion | -- |